Therapeutic activity of pretazettine on Rauscher leukemia: combination of antiviral activity and cellular protein inhibition

Chemotherapy. 1978;24(4):259-66. doi: 10.1159/000237790.

Abstract

Pretazettine hydrochloride (PTZ) has been found to inhibit protein synthesis, without being inhibitory to DNA and RNA, in Rauscher leukemic blood cells in mice for at least 6 h after its administration. With comparison to Virazole and cycloheximide, the specific anti-Rauscher virus activity of PTZ has been demonstrated only in acutely-infected NIH/3T3 cells but not in chronically-infected cells. It is not certain that the inhibitory action of PTZ on reverse transcriptase is contributory to its therapeutic activity in leukemic mice.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alkaloids / therapeutic use*
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cell Line
  • Cytotoxicity Tests, Immunologic
  • DNA, Neoplasm / biosynthesis
  • DNA-Directed DNA Polymerase / metabolism
  • Drug Evaluation, Preclinical
  • Leukemia, Experimental / drug therapy*
  • Macromolecular Substances
  • Mice
  • Neoplasm Proteins / biosynthesis
  • RNA, Neoplasm / biosynthesis
  • Rauscher Virus / drug effects

Substances

  • Alkaloids
  • Antineoplastic Agents
  • DNA, Neoplasm
  • Macromolecular Substances
  • Neoplasm Proteins
  • RNA, Neoplasm
  • DNA-Directed DNA Polymerase